| |
|
|
| |
Molecular Imaging Agents
Technology, Targets and Commercial Outlook
|
Publication: July 2010
Product Code: MIA710K
|
Driven by advances in molecular probe design and biomarker
detection methodologies, new imaging agents that can improve
visualization of pathologies and cellular processes are
changing the practice of diagnostic medicine. The ability of
this new generation of contrast agents to detect metabolic
changes at the molecular level has significant potential for
improving visualization and quality of care. Targetable and
activatable imaging agents are gaining interest for a wide
range of diagnostic applications that include cardiology,
neurology and soft tissue tumor detection. The number of
healthcare conditions that can be effectively imaged
noninvasively is expanding as a result of these innovative
detection technologies. Targeted and activatable imaging
agents offer a unique capability to generate unambiguous
images by exploiting specific molecular targets, pathways or
cellular processes. This new wave of imaging agents signals
a paradigm shift in which the reagents take on new
importance. |
|
Highlights |
· Analyzes and assesses
emerging imaging diagnostic candidates, their
capabilities, benefits, limitations and potential
· Profiles
development-stage imaging agents and examines their
clinical status and commercial prospects
· Analyzes key industry
alliances and partnerships by imaging modality, and
examines the impact of next-generation imaging
candidates on future imaging markets
· Profiles market
participants, their development activity and business
strategies
· Evaluates the impact of
economic, technology, and regulatory
factors on the development and
commercialization of emerging imaging
agents
|
|
Summary of Contents |
Executive Summary
Advanced Imaging Agents
- Market Dynamics
Targeted Therapy
The
Potential of Physiological Imaging
Molecular
Imaging – Current Successes
Market Drivers
Industry Alignment and Competitive Landscape
Differential Diagnosis
Diagnostic Imaging
Technology
Candidates and Strategies
Antibodies
Conjugated Radioisotopes
Lanthanide
Chelates
Metabolic Biomarkers
Optical Probes
Nanoparticles
Targeted Imaging Agents
Activatable Imaging Agents
Leading
Academic/Research Programs/Centers
Imaging
Modalities & the Potential of Molecular Imaging
MRI
Optical Imaging
PET
SPECT
Ultrasound
The Need for New Imaging Agents
Disease Detection
Image-Guided Drug Delivery
Physiological Process Mapping
Therapeutic
Screening
Treatment Assessment
Clinical
Applications –Near-Term Assessment and Future Impact
Physiological Visualization
Angiogenesis
Apoptosis
Inflammation
Disease Detection and
Therapeutic Management
Autoimmunity
Cardiology
Neurology
Oncology
Market Factors
Guidance, Rules and Regulations
Clinical
Validation
Alliances & Partnerships
Complementary Imaging Modalities and Hybrid Systems
Company Profiles
|
|
|
|
|
